Fosun International Shines Bright on Fortune's 2026 Chinese Companies List

Fosun International Shines on Fortune's 2026 List

On May 27, 2026, Fosun International Limited was proudly included in Fortune China magazine's prestigious list of "Most Admired Chinese Companies." This recognition highlights not only Fosun's business success but also its commitment to environmental, social, and corporate governance (ESG), employee welfare, and creating value for all stakeholders.

Fosun, headquartered in Hong Kong and listed on the Hong Kong Stock Exchange (HKEX: 00656), has steadily improved its standing in various international sustainability and ESG ratings. The company was recognized as an Industrial Star, a title that reflects its solid performance relative to competitors. Other notable companies featured on this list include giants like Tencent, Alibaba, and the Industrial and Commercial Bank of China, positioning Fosun among elite company.

Continuous Commitment to ESG

Fosun's unwavering dedication to sustainable development is evident in its numerous recognitions. Among these is its inclusion in the SP Global Sustainability Yearbook for 2026, where it ranked in the top 1% for three consecutive years. Furthermore, Fosun's Environmental, Social, and Governance (ESG) ratings have been consistently improving. It was upgraded to an AAA rating by MSCI, recognized by Hang Seng with an AA- rating, and received an impressive score of 4.2 from FTSE Russell, reflecting its commitment to sustainability metrics.

Fosun's strategies highlight its dual focus on innovation and corporate responsibility. In the health sector, the company strives to address unmet medical needs, focusing on critical areas such as oncology and biotechnology. For instance, the innovative Class 1 drug, luvometinib (branded as FUMAINING), has gained approval for treating rare diseases in mainland China, marking a significant step towards improving treatment options for patients.

Major Advancements and Contributions

At the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Fosun plans to present key findings from a Phase III study involving its new hematological treatment—lusometinib. The results aim to offer alternative treatment methods for adults with inoperable tumors, underscoring Fosun's dedication to impactful healthcare solutions.

Another promising product is HLX43, a potential leading figure in anti-tumor therapy, expected to showcase its clinical data at ASCO. This drug is currently undergoing international trials across varied regions including Europe and the U.S., indicating Fosun's broad scope in pharmaceutical innovations.

Moreover, Fosun Kairos is making strides in accessibility for cell therapies like Yi Kai Da, the first CAR-T cell product approved in Chinese mainland. By facilitating insurance coverage and increasing treatment centers available to the public, Fosun is committed to breaking down barriers for patients needing advanced therapy options.

Fosun's reach extends far beyond business success into substantial contributions to global health initiatives. As of late 2025, its independently developed artesunate injection has saved over 88 million patients suffering from severe malaria worldwide while introducing preventive measures benefiting over 330 million children in Africa. This success symbolizes Fosun's commitment to public health alongside corporate growth.

Addressing Climate Change

As part of its climate strategy, Fosun has actively responded to the national goals for carbon neutrality, pledging to peak carbon emissions by 2028 and achieve total carbon neutrality by 2050. The company has set intermediate targets to reduce greenhouse gas emissions by 20% by 2034—an ambitious plan demonstrating its leadership in the low-carbon transition. This commitment reflects Fosun's serious approach to environmental management and sustainability.

In a visible demonstration of its commitment, 97% of Club Med's resorts received Green Globe Certification, a mark of excellence in sustainability, indicating the effectiveness of Fosun's endeavors in making its operations eco-friendly.

Future Directions

Fosun International is not just resting on its laurels but is committed to furthering its industrial operations, enhancing its global presence, and continually improving its ESG pipeline. The company plans to align its strategies closely with sustainability goals while making strides in technological innovations and philanthropic efforts. Through this commitment, Fosun envisions creating happier lives for families worldwide, fostering long-term sustainable growth and maximizing stakeholder value.

In conclusion, Fosun International’s recognition on the 2026 Fortune list marks a significant milestone in its journey. As the company continues to push boundaries in health innovation and sustainability, it embodies a future where corporate success and social responsibility coexist to create a happier and healthier world.